ArticleBMC medical informatics and decision making2019
Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
Article in BMC medical informatics and decision making, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Drug-associated oropharyngeal infection: a real-world pharmacovigilance study using the FDA adverse event reporting system database.BMC oral health · 2026Article
- Medicine use during breastfeeding in Uganda: stakeholder perspectives on barriers and facilitators.International breastfeeding journal · 2025Article
- Article
- Impact of clinical pharmacist involvement on emergency department physicians' work-time distribution: a comparative analysis.Therapeutic advances in drug safety · 2025Article
- Adverse drug reaction signal detection via the long short-term memory model.Frontiers in pharmacology · 2025Article
- Article
- Accelerating adverse pregnancy outcomes research amidst rising medication use: parallel retrospective cohort analyses for signal prioritization.BMC medicine · 2024Article
- Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS).BMC pharmacology & toxicology · 2024Article
- A Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin versus Low-Molecular Weight Heparin.Clinical pharmacology : advances and applications · 2024Article
- An Early Adverse Drug Event Detection Approach with False Discovery Rate Control.medRxiv : the preprint server for health sciences · 2023Article
- Application of an Integrative Drug Safety Model for Detection of Adverse Drug Events Associated With Inhibition of Glutathione Peroxidase 1 in Chronic Obstructive Pulmonary Disease.Pharmaceutical research · 2023Article
- iADRGSE: A Graph-Embedding and Self-Attention Encoding for Identifying Adverse Drug Reaction in the Earlier Phase of Drug Development.International journal of molecular sciences · 2022Article
- Underreporting and Triggering Factors for Reporting ADRs of Two Ophthalmic Drugs: A Comparison between Spontaneous Reports and Active Pharmacovigilance Databases.Healthcare (Basel, Switzerland) · 2022Article
- Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.Journal of neurology · 2021Article
- Nephrotoxicity of Herbal Products in Europe-A Review of an Underestimated Problem.International journal of molecular sciences · 2021Review
- Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events.Frontiers in pharmacology · 2021Article
- Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAdverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of drug safety signal detection methods play an important role in providing drug safety insights. However, existing methods require sufficient case reports to generate signals, limiting their usages for newly approved drugs with few (or even no) reports.
methodsIn this study, we propose a label propagation framework to enhance drug safety signals by combining drug chemical structures with FDA Adverse Event Reporting System (FAERS). First, we compute original drug safety signals via common signal detection algorithms. Then, we construct a drug similarity network based on chemical structures. Finally, we generate enhanced drug safety signals by propagating original signals on the drug similarity network. Our proposed framework enriches post-market safety reports with pre-clinical drug similarity network, effectively alleviating issues of insufficient cases for newly approved drugs.
resultsWe apply the label propagation framework to four popular signal detection algorithms (PRR, ROR, MGPS, BCPNN) and find that our proposed framework generates more accurate drug safety signals than the corresponding baselines. In addition, our framework identifies potential ADRs for newly approved drugs, thus paving the way for early detection of ADRs.
conclusionsThe proposed label propagation framework combines pre-clinical drug structures with post-market safety reports, generates enhanced drug safety signals, and can potentially help to accurately detect ADRs ahead of time. AVAILABILITY: The source code for this paper is available at: https://github.com/ruoqi-liu/LP-SDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.